Abstract:Introduction Previous studies suggested that estrogen receptor alpha (ERα) plays an important role in the chemoresistance of breast cancers. However, large random trials failed to demonstrate any benefit of the concurrent estrogen antagonist tamoxifen on the chemotherapy efficacy. Thus, in the present study, the importance of the role of ERα in the chemoresistance of breast cancer cells was investigated. Methods The ERα-transfected Bcap37 cells and natural ERα-positive T47D breast cancer cells were treated using chemotherapeutic agents with or without 17-beta estradiol (E2) pretreatment. Their viabilities were assessed using 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide assays. The dead cell rates were determined using propidium iodide dye exclusion tests, and the expression levels of Bcl-2 and Bax were detected through Western blot analysis. The effects of E2 on the growth of breast cancer cells were also determined via cell growth curve and cell cycle analysis. Results ERα activation by E2 increased the sensitivity of natural ERα-positive T47D breast cancer cells to chemotherapeutic agents. However, the increase in ERα expression in ERα-negative Bcap37 breast cancer cells also significantly increased their resistance. These phenomena cannot be explained by asserting that ERα mediated the chemoresistance of breast cancer cells by regulating the expression of Bcl-2 and Bax. Our findings show that ERα activation upregulated the expression of Bcl-2 in natural ERα-positive T47D breast cancer cells, whereas ERα activation by E2 downregulated and upregulated the Bcl-2 and Bax expression levels, respectively, in ERα-transfected Bcap37 cells. This phenomenon was due to the influence of ERα on the growth of breast cancer cells. Specifically, ERα activation enhanced the growth of natural ERα-positive breast cancer cells and thus increased their sensitivity to chemotherapeutic agents. However, ERα activation also inhibited the growth of ERα-transfected Bcap37 cells and increased the resistance of cancer cells to chemotherapeutic agents. Chemoresistance of ERα-transfected Bcap37 cells was only due to the specific growth inhibition by E2, which is not applicable to common ERα-positive breast cancer cells. Conclusions Although ERα was associated with chemoresistance of breast cancers, ERα itself did not mediate this resistance process.

Estrogen Receptor-α36 is Involved in Pterostilbene-Induced Apoptosis and Anti-Proliferation in in Vitro and in Vivo Breast Cancer

Estrogen-independent Effects of ER-α36 in ER-negative Breast Cancer

Pterostilbene Simultaneously Induces Apoptosis, Cell Cycle Arrest and Cyto-Protective Autophagy in Breast Cancer Cells.

The role of estrogen receptor alpha in mediating chemoresistance in breast cancer cells

ER-α36: a Novel Biomarker and Potential Therapeutic Target in Breast Cancer.

Long Non-coding RNAs Contribute to the Inhibition of Proliferation and EMT by Pterostilbene in Human Breast Cancer

The therapeutic target of estrogen receptor-alpha36 in estrogen-dependent tumors

Estrogen Receptor-Α36 is Involved in Epigallocatechin-3-gallate Induced Growth Inhibition of ER-negative Breast Cancer Stem/progenitor Cells

Estrogen Receptor Α Variant ERα46 Mediates Growth Inhibition and Apoptosis of Human HT-29 Colon Adenocarcinoma Cells in the Presence of 17Β-Oestradiol

Pterostilbene Suppresses Human Endometrial Cancer Cells in Vitro by Down-Regulating Mir-663B.

Pterostilbene induces pyroptosis of breast cancer cells, inhibits the growth and invasion of transplanted tumor and reshapes its tumor microenvironment

A Variant of Estrogen Receptor-Alpha, Her-Alpha 36: Transduction of Estrogen- and Antiestrogen-Dependent Membrane-Initiated Mitogenic Signaling

Crosstalk Between Estrogen Receptor Alpha 36, A Dominant Extra-Nuclear Er, And Her2 Promotes Tumor Cell Survival In Breast Cancer

RETRACTED: Predictive and Prognostic Value of ER-α36 Expression in Breast Cancer Patients Treated with Chemotherapy

Pterostilbene Inhibits the Growth of Human Esophageal Cancer Cells by Regulating Endoplasmic Reticulum Stress

A Novel Combinatorial Epigenetic Therapy Using Resveratrol and Pterostilbene for Restoring Estrogen Receptor-α (ERα) Expression in ERα-Negative Breast Cancer Cells

P53, a Target of Estrogen Receptor (ER) Α, Modulates DNA Damage-induced Growth Suppression in ER-positive Breast Cancer Cells

Estrogen Receptor Β and Estrogen Receptor Α36 Predict Differential Outcome of Patients with Breast Cancer

Expression of ER-{alpha}36, a Novel Variant of Estrogen Receptor {alpha}, and Resistance to Tamoxifen Treatment in Breast Cancer.

Stable Knockdown of Estrogen Receptor Alpha by Vector-Based Rna Interference Suppresses Proliferation and Enhances Apoptosis in Breast Cancer Cells

Pterostilbene Mediates Neuroprotection Against Oxidative Toxicity Via Oestrogen Receptor Α Signalling Pathways.